lower extremity atherosclerotic occlusive disease
Conditions
Interventions
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Retrospective cohort inclusion criteria Patients will be included in this study if they meet ALL of the following criteria: 1. Diagnosed with lower extremity atherosclerotic occlusive disease and admitted for endovascular treatment between January 2017 and December 2023. 2. Complete lower extremity CTA images before the procedure or complete DSA images saved during the procedure. 3. First-time endovascular intervention for the target lesion in a single limb. 4. Complete baseline information, surgical records, pre-discharge ABI results, and 2-year follow-up information and outcome indicators. 5. Signed informed consent for biospecimen donation, agreeing that the donated samples and related information can be used for all medical research. Prospective cohort inclusion criteria: Patients will be included in this study if they meet ALL of the following criteria: 1. Diagnosed with lower extremity atherosclerotic occlusive disease. 2. Complete lower extremity CTA images before the procedure or complete DSA images saved during the procedure. 3. First-time endovascular intervention for the target lesion in a single limb. 4. Complete baseline information, surgical records, and pre-discharge ABI results. 5. Signed informed consent.
Exclusion criteria
Exclusion criteria: Retrospective cohort exclusion criteria: Patients will be excluded from this study if they have ANY of the following: 1. Severe heart, lung, or liver failure. 2. History of malignant tumor and not cured. 3. Life expectancy less than 2 years. 4. Unable to provide valid information on endpoint events. 5. Unable to provide complete medical history and follow-up endpoint events. Prospective cohort exclusion criteria: Patients will be excluded from this study if they have ANY of the following: 1. Severe heart, lung, or liver failure. 2. History of malignant tumor and currently active. 3. Life expectancy less than 2 years. 4. Unable to complete or tolerate examinations during follow-up. 5. Unable to provide complete medical history. 6. Unable to accept postoperative follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| main adverse limb event;Recurrent worsening of ischemic symptoms in the target limb;Sensitivity;Specificity;Accuracy;positive predictive value ;negative predictive value ; | — |
Secondary
| Measure | Time frame |
|---|---|
| all-cause death;Target vessel-related death;cardiovascular adverse event;Cerebrovascular adverse event; | — |
Countries
China
Contacts
Public ContactPan Tianyue
Zhongshan Hospital, Fudan University
Outcome results
None listed